Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic LeukemiaJennifer R. Brown, Mazyar Shadman, Lugui Qiu et al.|New England Journal of Medicine|2022Cited by 453
Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III TrialPeter Hillmen, Wojciech Jurczak, Barbara Eichhorst et al.|Journal of Clinical Oncology|2022Cited by 93
Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton’s tyrosine kinase inhibitor vecabrutinib in B-cell malignanciesJohn N. Allan, Jennifer R. Brown, Javier Pinilla‐Ibarz et al.|Haematologica|2021Cited by 37
Extended Follow-up of ALPINE Randomized Phase 3 Study Confirms Sustained Superior Progression-Free Survival of Zanubrutinib Versus Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL)Jennifer R. Brown, Mazyar Shadman, Barbara Eichhorst et al.|Blood|2023Cited by 24